Dr. Reddy’s Laboratories Limited to Post FY2026 Earnings of $4.11 Per Share, Zacks Research Forecasts (NYSE:RDY)

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Research analysts at Zacks Research cut their FY2026 earnings per share estimates for Dr. Reddy’s Laboratories in a research report issued to clients and investors on Tuesday, April 16th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $4.11 for the year, down from their previous forecast of $4.12. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $3.96 per share.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.99 EPS for the quarter, topping the consensus estimate of $0.88 by $0.11. Dr. Reddy’s Laboratories had a return on equity of 20.97% and a net margin of 19.26%. The firm had revenue of $867.00 million for the quarter, compared to the consensus estimate of $827.81 million.

Several other analysts have also recently issued reports on the company. StockNews.com upgraded Dr. Reddy’s Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 5th. Jefferies Financial Group cut Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a research report on Thursday, January 11th. Finally, Barclays increased their target price on Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the stock an “overweight” rating in a research report on Monday, January 29th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Dr. Reddy’s Laboratories presently has a consensus rating of “Hold” and an average price target of $80.00.

Dr. Reddy’s Laboratories Stock Down 0.3 %

NYSE RDY opened at $71.37 on Wednesday. The stock’s 50-day moving average price is $74.54 and its 200-day moving average price is $70.17. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories has a 52 week low of $53.12 and a 52 week high of $77.72. The company has a market capitalization of $11.91 billion, a P/E ratio of 18.83, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58.

Hedge Funds Weigh In On Dr. Reddy’s Laboratories

Several institutional investors have recently added to or reduced their stakes in RDY. Aikya Investment Management Ltd purchased a new position in Dr. Reddy’s Laboratories during the 4th quarter valued at approximately $75,850,000. Bank of America Corp DE grew its holdings in Dr. Reddy’s Laboratories by 1,016.4% during the 1st quarter. Bank of America Corp DE now owns 514,796 shares of the company’s stock valued at $29,307,000 after buying an additional 468,685 shares in the last quarter. BlackRock Inc. grew its holdings in Dr. Reddy’s Laboratories by 25.1% during the 1st quarter. BlackRock Inc. now owns 2,303,063 shares of the company’s stock valued at $131,113,000 after buying an additional 462,799 shares in the last quarter. Marshall Wace LLP grew its holdings in Dr. Reddy’s Laboratories by 809.4% during the 2nd quarter. Marshall Wace LLP now owns 246,912 shares of the company’s stock valued at $15,583,000 after buying an additional 219,762 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its holdings in Dr. Reddy’s Laboratories by 15.0% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 1,673,126 shares of the company’s stock valued at $111,882,000 after buying an additional 218,605 shares in the last quarter. Hedge funds and other institutional investors own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.